Of interest, efgartigimod (ARGX-113), a new FcRn blocker, is a human IgG1 Fc fragment engineered to reduce pathogenic IgG autoantibody levels showing promising results in neurological autoimmune disorders, such as MG. Here, FCGRT is linked to myasthenia gravis.